PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34862634-1	2022	Twelve new triazolo(4,3-a)quinoxaline-based compounds are reported as anticancer agents with potential effects against vascular endothelial growth factor receptor-2 (VEGFR-2), using sorafenib as a reference molecule.	Sorafenib	182-191	kinase insert domain receptor	Homo sapiens	166-173	
34862634-3	2022	The most powerful VEGFR-2 inhibitor was compound 14a, which had an IC50 value of 3.2 nM, which is very close to that of sorafenib (IC50  = 3.12 nM).	Sorafenib	120-129	kinase insert domain receptor	Homo sapiens	18-25